Pfizer Inc. Stock
€26.45
Your prediction
Pfizer Inc. Stock
Pros and Cons of Pfizer Inc. in the next few years
Pros
Cons
Performance of Pfizer Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | 0.860% | 1.529% | 7.855% | -23.875% | 0.479% | -20.410% | -23.958% |
| Biogen Inc. | 1.760% | 2.996% | 12.530% | -26.473% | -11.069% | -9.142% | 2.218% |
| Elanco Animal Health Inc. | 0.420% | 25.513% | 16.882% | 99.646% | 16.657% | -44.969% | - |
| AbbVie Inc. | 0.380% | -1.178% | -2.163% | 10.088% | 6.552% | 55.695% | 110.967% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon first glance, the financials of Pfizer Inc. (NYSE: PFE) appear to be strong, showcasing a robust position in the pharmaceuticals industry. As a prominent player, Pfizer has consistently demonstrated growth in its total assets and revenue, laying the foundation for a favorable outlook on the company's performance. As we dive deeper into the financial statements, it becomes essential to analyze the pros and cons to acquire a comprehensive understanding of Pfizer's financial health and future potential.
*Pros: *
Growing Total Assets and Shareholders' Equity: The company's total assets have grown consistently over the past three years, from approximately €154.2 billion in 2020 to €181.5 billion in 2021, and reaching a notable USD 197.2 billion in 2022. Such growth indicates strong financial management and an increased capacity to generate income. Similarly, the total stockholder equity has also risen, reflecting the company's ability to create value for its shareholders.
Comments
News
2 Healthcare Stocks to Buy and Hold for Great Long-Term Potential
Your long-term investment portfolio should have meaningful exposure to healthcare stocks. People will always seek treatments for disease, so demand for the sector won't go away any time soon
Want $1,000 in Dividend Income? Here's How Much You'd Have to Invest in Pfizer Stock
Pfizer (NYSE: PFE) stock has struggled over the past year, losing around 28% of its value. Its dividend payout, meanwhile, has continued to rise again and again. This combination has pushed the
2 Beaten-Down Stocks to Buy and Hold for 10 Years
It's easy to find stocks that are lagging broader equities, even in a bull market like the one we're currently in. It's harder to find beaten-down stocks that still look worth buying and holding